4Li Y, Xu W, Liao J, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with im- provement of beta-cell function [ J ]. Diabetes Care, 2004, 27 ( 11 ) :2957-2602.
6Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diag- nosed type 2 diabetes : a multicentre randomised parallel group trial [Jl. Lancet, 2008,371 (9626) :1753-1760.
7Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of in- tensive glucose control in type 2 diabetes [ J ]. N Engl J Med, 2008,359 ( 15 ) : 1577-1589.
4Weyer. Dificiency in AIR predict IGT and Type 2 diabetes. Diabetes Care, 2001,24 : 89-94.
5Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes, 1995,44: 1386-1391.
6Bruce DG, Chisholm DJ, Leonare H, et al. Physiological importance of deficiency in early prandial insulin secretion in non-in-sulin-dependent diabetes. Diabetes, 1988,37: 736-743.
7Bruttomesso D, Pianta A, Mari A, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes, 1999,48: 99-105.
8Ilkova H, glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20:1353-1356.
9Walton C, Godsland IF, Proudler AJ, et al. Effect of body mass index and fat distribution on insulin sensitivity, secretion, and clearance in nonobese healthy men. J Clin Endocrinol Metab,1992,75: 170-175.
10McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001; 61:1599 - 624.
